Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial

医学 静脉血栓栓塞 临床终点 打开标签 随机对照试验 外科 血栓形成
作者
Françis Couturaud,Jeannot Schmidt,Olivier Sanchez,Alice Ballerie,Marie‐Antoinette Sevestre,Nicolas Méneveau,Laurent Bertoletti,J. Connault,Y. Benhamou,J. Constans,T. Quéméneur,François-Xavier Lapébie,Gilles Pernod,Gaël Picart,Antoine Élias,C. Doutrelon,Claire Neveux,Lina Khider,P.M. Roy,Stéphane Zuily
出处
期刊:The Lancet [Elsevier BV]
卷期号:405 (10480): 725-735 被引量:1
标识
DOI:10.1016/s0140-6736(24)02842-3
摘要

In patients with venous thromboembolism at high risk of recurrence for whom extended treatment with direct oral anticoagulants has been indicated, the optimal dose is unknown. We aimed to assess efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in patients in whom extended anticoagulation has been indicated. RENOVE was a non-inferiority, investigator-initiated, multicentre, randomised, open-label, blinded endpoint trial done in 47 hospitals in France. Ambulatory patients aged 18 years or older with acute symptomatic venous thromboembolism (pulmonary embolism or proximal deep vein thrombosis) who had received 6-24 uninterrupted months of full-dose anticoagulation and for whom extended anticoagulation has been indicated were eligible. Eligible participants were categorised as having either a first unprovoked venous thromboembolism, recurrent venous thromboembolism, presence of persistent risk factors, or other clinical situations considered to be a high risk of recurrence. Participants were randomly assigned (1:1) to receive oral treatment with either a reduced dose of apixaban (2·5 mg twice daily) or rivaroxaban (10 mg once daily) or a full dose of apixaban (5 mg twice daily) or rivaroxaban (20 mg once daily) using a centralised randomisation procedure with an interactive web response system. The sequence generation method was a computerised random number generator and was balanced by blocks of different sizes. Randomisation was stratified by centre, type of direct oral anticoagulant, and antiplatelet drug. Physicians and participants were unmasked to treatment allocation; recurrent venous thromboembolism, clinically relevant bleeding, and all-cause death were adjudicated by an independent committee blinded to treatment allocation. The primary outcome was symptomatic recurrent venous thromboembolism, including recurrent fatal or non-fatal pulmonary embolism or isolated proximal deep vein thrombosis (non-inferiority hypothesis 90% power to exclude a hazard ratio [HR] of 1·7). The primary outcome and first two secondary outcomes were included in a hierarchical testing procedure. This trial is registered with ClinicalTrials.gov, NCT03285438. From Nov 2, 2017, to July 6, 2022, 2768 patients were enrolled and randomly assigned to the reduced-dose group (n=1383) or the full-dose group (n=1385). 970 (35·0%) participants were female, 1797 (65·0%) were male, and one (<0·1%) had sex not reported. Median follow-up was 37·1 months (IQR 24·0-48·3). Recurrent venous thromboembolism occurred in 19 of 1383 patients in the reduced-dose group (5-year cumulative incidence 2·2% [95% CI 1·1-3·3]) versus 15 of 1385 patients in the full-dose group (5-year cumulative incidence 1·8% [0·8-2·7]; adjusted HR 1·32 [95% CI 0·67-2·60]; absolute difference 0·40% [95% CI -1·05 to 1·85]; p=0·23 for non-inferiority). Major or clinically relevant bleeding occurred in 96 patients in the reduced-dose group (5-year cumulative incidence 9·9% [95% CI 7·7-12·1]) and 154 patients in the full-dose group (5-year cumulative incidence 15·2% [12·8-17·6]; adjusted HR 0·61 [95% CI 0·48-0·79]). 1136 (82·1%) of 1383 patients in the reduced-dose group and 1150 (83·0%) of 1385 in the full-dose group had an adverse event; 374 (27·0%) patients in the reduced-dose group and 420 (30·3%) in the full-dose group has a serious adverse event. 35 (5-year cumulative incidence 4·3% [95% CI 2·6-6·0]) patients in the reduced-dose group and 54 (5-year cumulative incidence 6·1% [4·3-8·0]) patients in the full-dose group died during the study period. In patients with venous thromboembolism requiring extended anticoagulation, reduction of the direct oral anticoagulant dose did not meet the non-inferiority criteria. However, the low recurrence rates in both groups and substantial reduction of clinically relevant bleeding with the reduced dose could support this regimen as an option. Further research will be needed to identify subgroups for whom the anticoagulation dose should not be reduced. French Ministry of Health.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
幸福的鑫鹏完成签到,获得积分10
刚刚
孤海未蓝完成签到,获得积分10
1秒前
彭于晏应助飒飒采纳,获得10
2秒前
狠毒的小龙虾完成签到,获得积分10
3秒前
小趴菜完成签到,获得积分10
7秒前
lcls完成签到,获得积分10
8秒前
8秒前
9秒前
尊敬太阳发布了新的文献求助10
11秒前
风中夜天完成签到 ,获得积分10
11秒前
优雅友蕊完成签到,获得积分10
12秒前
gaga完成签到,获得积分10
13秒前
西北孤傲的狼完成签到,获得积分10
14秒前
多边形完成签到 ,获得积分10
16秒前
李cc完成签到,获得积分10
18秒前
18秒前
快帮我找找完成签到,获得积分10
18秒前
xiezhuochun完成签到 ,获得积分10
19秒前
22秒前
aixiaoming0503完成签到,获得积分10
23秒前
forge完成签到,获得积分10
23秒前
24秒前
Distance完成签到,获得积分10
27秒前
蒋念寒发布了新的文献求助10
28秒前
雪雨夜心完成签到,获得积分10
32秒前
又是一年完成签到,获得积分10
33秒前
Distance发布了新的文献求助10
34秒前
李子完成签到 ,获得积分10
35秒前
35秒前
耍酷的指甲油完成签到,获得积分20
36秒前
安小磊完成签到 ,获得积分10
37秒前
雄i完成签到,获得积分10
40秒前
明亮的遥完成签到 ,获得积分0
42秒前
安澜完成签到,获得积分10
42秒前
MG_XSJ应助1111采纳,获得10
45秒前
尊敬太阳完成签到,获得积分20
46秒前
47秒前
量子星尘发布了新的文献求助30
48秒前
健壮安柏完成签到 ,获得积分10
49秒前
Jasper应助忧郁紫翠采纳,获得10
50秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022